2024

1. A Prospective, Multicenter, Real-World Registry of Coronary Lithotripsy in Calcified Coronary Arteries: The REPLICA-EPIC18 Study

   JACC: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 756-767

2. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

   Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

3. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

   Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

4. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

   Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

5. Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus

   BMJ Open Gastroenterology, Vol. 11, Núm. 1

6. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

   eClinicalMedicine, Vol. 71

7. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

   Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

8. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

   Annals of Hematology

9. Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch

   Transplantation, Vol. 108, Núm. 3, pp. 787-801

10. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology

11. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients

    Journal of the European Academy of Dermatology and Venereology

12. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

    Bone Marrow Transplantation

13. Older Adult Patients in the Emergency Department: Which Patients should be Selected for a Different Approach?

    Annals of Geriatric Medicine and Research, Vol. 28, Núm. 1, pp. 9-19

14. Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results

    HemaSphere

15. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14

16. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

17. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

    Haematologica, Vol. 109, Núm. 3, pp. 877-887

18. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217

19. Risk factors for intraoperative hypertensive crisis in patients with pheochromocytomas and sympathetic paragangliomas

    Journal of Hypertension, Vol. 42, Núm. 2, pp. 252-259

20. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

    Clinical and Translational Oncology